首页> 美国卫生研究院文献>Pharmacogenomics and Personalized Medicine >Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

【2h】

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

机译：CYP2D6和CYP2C19多态性与接受他莫昔芬辅助治疗的泰国绝经后乳腺癌患者无病生存的关系

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeTo investigate the impact of CYP2D6 and CYP2C19 polymorphisms in predicting tamoxifen efficacy and clinical outcomes in Thai breast cancer patients.

机译：目的探讨CYP2D6和CYP2C19多态性在预测他莫昔芬疗效和泰国乳腺癌患者临床结局中的作用。

著录项

期刊名称 Pharmacogenomics and Personalized Medicine
作者
Montri Chamnanphon; Khunthong Pechatanan; Ekapob Sirachainan; Narumol Trachu; Wasun Chantratita; Ekawat Pasomsub; Wilai Noonpakdee; Insee Sensorn; Chonlaphat Sukasem;
展开▼
作者单位

展开▼
年(卷),期 2013(6),-1
年度 2013
页码 37–48
总页数 12
原文格式 PDF
正文语种
中图分类药学;
关键词
CYP2D6 CYP2C19 disease-free survival tamoxifen pharmacogenetics breast cancer;

机译：CYP2D6;CYP2C19;无病生存期;他莫昔芬;药物遗传学;乳腺癌;

相似文献

外文文献
中文文献
专利

1. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen [J] . Montri Chamnanphon, Khunthong Pechatanan, Ekapob Sirachainan, Pharmacogenomics and Personalized Medicine . 2013,第1期

机译：CYP2D6和CYP2C19基因多态性与接受他莫昔芬辅助治疗的泰国绝经后乳腺癌患者无病生存的关系
2. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. [J] . Goetz M, Suman V Cancer: A Journal of the American Cancer Society . 2010,第4期

机译：CYP2D6 * 10和CYP2C19 * 2 * 3的遗传多态性与他莫昔芬辅助治疗的日本乳腺癌患者的预后，子宫内膜厚度或骨矿物质密度无关。
3. Reply to Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen [J] . Shinzaburo Noguchi MD Masatsugu Okishiro MD Cancer . 2010,第4期

机译：CYP2D6 * 10和CYP2C19 * 2 * 3的基因多态性与他莫昔芬辅助治疗的日本乳腺癌患者的预后，子宫内膜厚度或骨矿物质密度无关
4. Association of CYP2D6 and ADRB1 Single Nucleotide Polymorphisms and Response to Beta Blocker Therapy in a Patient Sample Set with Cardiovascular Diseases from Romania [C] . Andrada Camelia Guta, Liana Gabriela Gruescu Molecular Medicine TRI-CON. . 2014

机译：CYP2D6和ADRB1单核苷酸多态性和对患者样本中β受体疗法的响应与来自罗马尼亚的心血管疾病
5. Dietary associations with biomarkers of breast cancer risk in women on adjuvant tamoxifen therapy. [D] . Strom, Meghan Brianna. 2016

机译：辅助性他莫昔芬治疗妇女饮食中与乳腺癌风险生物标志物的关联。
6. CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients [O] . Ekaphop Sirachainan, Sureerat Jaruhathai, Narumol Trachu, 2012

机译：CYP2D6基因多态性影响他莫昔芬在泰国乳腺癌患者中的疗效
7. Reply to Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen [O] . Shinzaburo Noguchi, Masatsugu Okishiro 2010

机译：回复CYP2D6 * 10和CYP2C19 * 2，* 3的遗传多态性与日本乳腺癌患者治疗的日本乳腺癌患者中的预后，子宫内膜厚度或骨密度无关

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅